Nevertheless, significant clinical benefit has been demonstrated for ATLL patients treated with AZT and IFN-α combination therapy and HAM/TSP patients treated with IFN-α monotherapy [7,51,52]. The gene discussed is IFNA2; the disease is tropical spastic paraparesis.